print_label | resize_label
 

TAGRISSO safety profile1

 

Adverse reactions occurring in ≥10% (for all grades) of TAGRISSO- and doublet chemotherapy-treated patients1

  • No Grade 4 events were reported
  • No single serious adverse reaction was reported in 2% or more of patients treated with TAGRISSO
TAGRISSO® (osimertinib) Side Effects TAGRISSO® (osimertinib) Side Effects

*NCI CTCAE v4.0.

  1. No Grade 4 events were reported.
  2. Includes rash, rash generalized, rash erythematous, rash macular, rash maculopapular, rash papular, rash pustular, erythema, folliculitis, acne, dermatitis, and acneiform dermatitis.
  3. Includes dry skin, eczema, skin fissures, xerosis.
  4. Includes nail disorders, nail bed disorders, nail bed inflammation, nail bed tenderness, nail discoloration, nail dystrophy, nail infection, nail ridging, nail toxicity, onychoclasis, onycholysis, onychomadesis, paronychia.
  5. Includes pruritus, pruritus generalized, eyelid pruritus.
  6. Includes fatigue, asthenia.

Common laboratory abnormalities (>20% for all grades) in AURA31

Common Laboratory Abnormalities Common Laboratory Abnormalities Common Laboratory Abnormalities Common Laboratory Abnormalities

gBased on the number of patients with available follow-up laboratory data.

TAGRISSO® (osimertinib) Dosage Reduction Information TAGRISSO® (osimertinib) Dosage Reduction Information TAGRISSO® (osimertinib) Dosage Reduction Information